Watch Jim Cramer's interview with Johnson & Johnson CEO Joaquin Duato

Johnson & Johnson: Mad Money Interview Summary

Key Concepts:

• Pharmaceutical Innovation & R&D
• US Manufacturing Investment
• Cell Therapy (Multiple Myeloma)
• Bladder Cancer Treatment (Electra)
• Cardiovascular Devices (Abiomed, Shockwave)
• Daubert Hearing (Talc Lawsuits)
• Drug Pricing & Access
• Pipeline of Innovation

1. Investment in US Manufacturing & Impact of Tax Reforms:

• Johnson & Johnson (J&J) is investing $55 billion in the US over the next four years, a 25% increase compared to the previous four years.
• This investment is attributed to the Trump tax reforms enacted in 2017 and now confirmed.
• The company is breaking ground on a major biologics plant in North Carolina.
• The goal is to manufacture essentially all advanced medicines in the US, creating middle-class jobs in robotics, cell therapy, and biologics.
• J&J emphasizes its commitment to the US, highlighting its 140-year presence in New Brunswick, New Jersey.

2. Advancements in Human Health & the Role of AI:

• The CEO believes the next decade will see more advancements in human health than the last century.
• This is driven by advances in biology and chemistry, amplified by technology and artificial intelligence (AI).
• The combination of these factors is expected to lead to cures for diseases previously considered incurable, such as cancer and dementia.

3. Cell Therapy for Multiple Myeloma:

• J&J has been working on a cure for multiple myeloma, a devastating disease.
• Their cell therapy has shown promising results, with patients who were about to enter hospice being disease-free five years after a single administration.

4. Bladder Cancer Treatment (Electra):

• J&J has received FDA approval for Electra, a groundbreaking therapy for localized bladder cancer.
• Electra is a drug-releasing system that delivers cancer treatment directly into the bladder.
• It has shown tremendous and durable responses, potentially allowing patients to keep their bladder, avoiding its removal and improving quality of life.
• This exemplifies J&J's capabilities in combining medicines and medical devices.

5. Cardiovascular Device Acquisitions (Abiomed & Shockwave):

• Abiomed, acquired by J&J, produces heart pumps that take over the heart's function during a heart attack.
• Data presented at a European Congress and published in the New England Journal of Medicine showed that patients with cardiogenic shock who used Abiomed's heart pumps lived 600 days longer over a ten-year period.
• This is attributed to the heart pumps allowing the heart to rest and recover.

6. The US as a Hub for Innovation:

• The CEO believes the US is the best country for innovation in life sciences, echoing Warren Buffett's sentiment of "never bet against America."
• The US has the necessary elements: universities, research institutions, talent, capital markets, and companies like J&J.
• Despite concerns about government attacks on research, the CEO remains optimistic about the strength of the life science industry in the US.

7. Talc Lawsuits & Daubert Hearing:

• J&J is taking a firm stance against the talc lawsuits, believing the charges will not hold up in court.
• The company is focused on the Daubert hearing, where the court will reevaluate the "junk science" presented by the claimants' attorneys.
• Since returning to the tort system, J&J has not paid a single penny in these cases.
• J&J has won 16 out of 17 ovarian cancer cases in the last 11 years.

8. Tylenol Concerns:

• The CEO defers to the FDA and Kenvue (the company that now owns Tylenol) regarding concerns about Tylenol's safety.
• J&J separated from Kenvue two years ago and does not have information on their decisions.

9. Drug Pricing & Access:

• J&J aims to save lives with its medicines and ensure every American can afford them.
• The company prioritizes appropriate access for every American when bringing a drug to market.

10. Financial Performance & Future Outlook:

• J&J had a stellar Q2, exceeding analysts' expectations and substantially increasing guidance.
• The company expects 2026 to be better than 2025, and 2027 to be better than 2026, driven by its pipeline of innovation.
• The stock is considered inexpensive, with a 3% yield and a triple-A balance sheet.

Synthesis/Conclusion:

The interview paints a picture of Johnson & Johnson as a company deeply invested in innovation, particularly in areas like cell therapy, cancer treatment, and cardiovascular devices. They are making significant investments in US manufacturing and are optimistic about the future of healthcare innovation in the country. While facing challenges related to lawsuits and drug pricing concerns, the company remains confident in its pipeline, financial performance, and commitment to improving patient outcomes. The CEO emphasizes the role of AI in accelerating medical breakthroughs and highlights J&J's dedication to ensuring access to its medicines.